このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (IRIS)

Phase II Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events (The IRIS Trial: Immune Checkpoint Inhibitor Rechallenge Involving Sarilumab)

The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm study after meeting the pre-specified eligibility criteria

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

41

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Danielle Wendler
  • 電話番号:410-502-5140
  • メール:JHCTN@jhmi.edu

研究連絡先のバックアップ

  • 名前:Chelsea Miralles
  • 電話番号:410-955-9923
  • メール:cmirall1@jhmi.edu

研究場所

    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
        • コンタクト:
          • Danielle Wendler
          • 電話番号:410-502-5140
          • メール:JHCTN@jhmi.edu
        • コンタクト:
        • 主任研究者:
          • Aliyah Pabani, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Eligible patients include patients with malignancy treated with ICI, who have been diagnosed with a clinically significant irAE (grade 1-3 attributed to ICI per CTCAE v6.0) requiring interruption of ICI by the treating physician. This study is limited to patients with the following specific irAEs as IL-6R blockade has demonstrated effectiveness in these conditions. Specific toxicities eligible for inclusion are; arthritis, colitis, PMR, nephritis, pneumonitis, hepatitis, myositis

  • The risk/benefit profile must favor ICI rechallenge as deemed per treating oncologist

  • The irAE must have improved to grade 1 by CTCAE criteria v6.0 for at least 1 week (exception for patients who have endocrinopathies which will typically require lifelong hormone supplementation)

  • Be willing and able to provide informed consent/assent for the trial

  • Be ≥18 years of age on the day of signing informed consent

  • Female subject of childbearing potential must have a negative urine or serum pregnancy test within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Women of child-bearing potential (WOCBP):

    • Agree to use contraception while participating in this study, and for a period of 6 months following last dose of Sarilumab or ICI, as effects of these agents on the developing human fetus are unknown. Men whose partner is a WOCBP must also agree to use contraception during this period. Negative pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within two weeks of registration. Women must not be breastfeeding or plan to breastfeed for the duration of therapy or 6 months after.
  • Males must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 3 months after last dose of sarilumab, 120 days even if he has undergone a successful vasectomy

  • Have adequate organ function as described below

    • Absolute neutrophil count (ANC) ≥500/mm3
    • Platelets ≥ 50,000/mm3
    • AST/ALT <=3× institutional upper limit of normal
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  • Completed informed consent process, including signing Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.

  • Willing and able to comply with clinical trial instructions and requirements. Subjects must be competent to report AEs, understand the drug dosing schedule, and use of medications to control AEs

Exclusion Criteria:

  • History of grade 4 irAE (attributed to ICI per CTCAE v6.0)
  • History of cardiovascular or neurologic immune related adverse event
  • Active or serious infections
  • History of latent Tuberculosis (TB) or uncontrolled hepatitis B/C
  • History of gastrointestinal perforation or diverticulitis
  • Severe hepatic impairment (AST, ALT >3xULN; total bilirubin >1.5xULN)
  • Significant hematological abnormalities
  • On prednisone equivalent >10mg prior to first dose of trial treatment
  • History of immunodeficiency disorder
  • Treatment with a non-biologic immunosuppressive or immune-modulating drug (e.g. methotrexate, azathioprine, mycophenolate, cyclosporine, hydroxychloroquine, penicillamine) at time of enrollment
  • Treatment with other immune-modulating biologic agents (e.g TNF-alpha inhibitors) within 8 weeks prior to enrollment
  • History of anaphylaxis or IgE-mediated hypersensitivity to sarilumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to sarilumab.
  • The subject must meet all of the inclusion criteria and none of the exclusion criteria.

No eligibility waivers will be granted.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sarilumab with ICI

Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator.

Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks.

ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
時間枠:From enrollment to the end of treatment at 53 weeks

Absence of any grade ≥2 Immune Related Adverse Event (irAE) in the 3 months after ICI rechallenge, defined as grade ≥2 adverse event attributed to ICI by CTCAE v6.0

From enrollment to the end of treatment at 53 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Safety and tolerability as assessed by occurrence of adverse events
時間枠:From enrollment to the end of treatment at 53 weeks

Safety and tolerability will be measured by occurrence of grade ≥3 adverse events as measured by CTCAE v6.0 and patient reported outcomes (PROs) as assessed by PRO-CTCAE v1.0.

From enrollment to the end of treatment at 53 weeks
Absence of Serious immune-related adverse event
時間枠:From enrollment to the end of treatment at 53 weeks

To assess to the safety of Immune Checkpoint Inhibitor (ICI) rechallenge with sarilumab with respect to serious irAE of grade ≥2 in patients with a history of non- cardiovascular and non-neurologic clinically significant irAEs.

From enrollment to the end of treatment at 53 weeks
Efficacy as assessed by progression free survival
時間枠:From enrollment to the end of treatment at 53 weeks

Cancer outcomes will be measured by progression free survival (PFS). PFS is defined as the time from first dose of sarilumab + ICI rechallenge until investigator-assessed radiological progressive disease (PD) or death, whichever comes first.

From enrollment to the end of treatment at 53 weeks
Efficacy as assessed by Overall survival
時間枠:From enrollment to the end of treatment at 53 weeks

Cancer outcomes will be measured by overall survival (OS).Overall survival is defined as the time from first dose of sarilumab + ICI rechallenge until death.

From enrollment to the end of treatment at 53 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Aliyah Pabani, MD、Johns Hopkins University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2029年8月1日

研究の完了 (推定)

2029年12月1日

試験登録日

最初に提出

2026年9月17日

QC基準を満たした最初の提出物

2026年9月17日

最初の投稿 (実際)

2026年9月23日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月28日

QC基準を満たした最後の更新が送信されました

2026年10月27日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • J2687
  • 15845 (その他の助成金/資金番号:Robert A. Winn Excellence in Clinical Trials Award)
  • IRB00559848 (その他の識別子:Johns Hopkins IRB)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。